Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Privacy Notice – Cookies & Website/Application Data

This Privacy Notice – Cookies & Website/Application Data explains how Hovione collects and uses data through cookies and similar technologies on our website and applications.

Page
Read more

Drug Product Manufacturing

To extend Hovione further we are now able to offer clinical supplies manufacturing for drug products.

Page
Read more

Development

Hovione offers a full range of development services in particle engineering to provides optimal solutions for your drug product.

Page
Read more